Key Points
- GeneDx director Keith Meister purchased 29,495 shares on March 3 at an average price of $70.89, a $2.09M transaction that raised his total holding to 3,088,124 shares (about $219M), a 0.96% ownership increase.
- The buy is part of larger insider/institutional interest — Meister also bought 140,026 shares on March 5 (~$11.37M) and Corvex Management acquired roughly $13.4M of stock — signaling insider/institutional confidence.
- Insider activity is mixed: CEO and CFO sold shares on March 4, while the stock traded up ~4.2% and GeneDx recently beat quarterly EPS estimates ($0.14 vs. $0.11) on roughly $121M in revenue.
GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 6,187 shares of GeneDx stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $78.61, for a total value of $486,360.07. Following the completion of the transaction, the chief financial officer owned 18,674 shares in the company, valued at $1,467,963.14. This represents a 24.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Kevin Feeley also recently made the following trade(s):
- On Thursday, January 29th, Kevin Feeley sold 317 shares of GeneDx stock. The stock was sold at an average price of $93.99, for a total value of $29,794.83.
- On Tuesday, December 16th, Kevin Feeley sold 3,855 shares of GeneDx stock. The shares were sold at an average price of $143.87, for a total value of $554,618.85.
- On Tuesday, December 9th, Kevin Feeley sold 1,266 shares of GeneDx stock. The shares were sold at an average price of $159.28, for a total value of $201,648.48.
GeneDx Stock Up 4.0%
Shares of WGS stock traded up $3.31 during mid-day trading on Friday, hitting $85.31. 346,518 shares of the stock traded hands, compared to its average volume of 769,397. GeneDx Holdings Corp. has a 52-week low of $55.17 and a 52-week high of $170.87. The stock has a market cap of $2.50 billion, a P/E ratio of -113.75 and a beta of 2.03. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.46 and a quick ratio of 2.34. The stock's fifty day moving average is $101.71 and its two-hundred day moving average is $122.42.
GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings data on Monday, February 23rd. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.11 by $0.03. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. The firm had revenue of $120.99 million during the quarter, compared to analyst estimates of $120.80 million. Equities analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current year.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on the company. Weiss Ratings restated a "sell (d)" rating on shares of GeneDx in a research note on Wednesday, January 21st. Canaccord Genuity Group boosted their price target on GeneDx from $160.00 to $170.00 and gave the stock a "buy" rating in a research note on Monday, December 22nd. BTIG Research decreased their price objective on shares of GeneDx from $200.00 to $170.00 and set a "buy" rating for the company in a research report on Tuesday, February 24th. Jefferies Financial Group set a $150.00 target price on shares of GeneDx in a research note on Monday, February 23rd. Finally, Piper Sandler restated an "overweight" rating and set a $130.00 price target (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $150.71.
Get Our Latest Stock Report on WGS
Institutional Investors Weigh In On GeneDx
A number of institutional investors and hedge funds have recently modified their holdings of the company. Rhumbline Advisers increased its holdings in GeneDx by 42.7% in the 2nd quarter. Rhumbline Advisers now owns 27,610 shares of the company's stock worth $2,549,000 after buying an additional 8,258 shares during the period. Principal Financial Group Inc. lifted its stake in GeneDx by 340.4% during the 3rd quarter. Principal Financial Group Inc. now owns 59,624 shares of the company's stock valued at $6,424,000 after acquiring an additional 46,085 shares during the period. ARK Investment Management LLC purchased a new stake in shares of GeneDx in the 3rd quarter valued at $48,157,000. Impax Asset Management Group plc acquired a new stake in shares of GeneDx in the third quarter worth $5,387,000. Finally, Legal & General Group Plc raised its holdings in shares of GeneDx by 55.9% during the second quarter. Legal & General Group Plc now owns 22,271 shares of the company's stock worth $2,056,000 after purchasing an additional 7,987 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company's stock.
Trending Headlines about GeneDx
Here are the key news stories impacting GeneDx this week:
- Positive Sentiment: Large affiliated purchase: Corvex Management reported a purchase of GeneDx shares worth roughly $13.4 million, signaling institutional/insider confidence that can support the stock. Corvex management buys GeneDx (WGS) shares worth $13.4 million
- Positive Sentiment: Director purchases: Director Keith A. Meister made two recent buys — 140,026 shares on Mar 5 at ~$81.19 (~$11.37M) and 29,495 shares on Mar 3 at ~$70.89 (~$2.09M) — increasing his stake to over 3.2M shares. Large insider buys by a director typically signal confidence and can spur investor demand. SEC ownership filing — Keith A. Meister purchases
- Neutral Sentiment: Short-interest data shows 0 reported short interest as of Mar 5 (days-to-cover 0.0), which appears to be a data anomaly or non-material reading; it provides little actionable signal for directional pressure.
- Negative Sentiment: CEO sale: CEO Katherine Stueland sold 25,459 shares on Mar 4 at an average ~$78.61 (~$2.00M), reducing her direct ownership by ~39.7%. Significant insider sales can prompt investor concern about insiders taking liquidity. SEC Form 4 — CEO sale
- Negative Sentiment: CFO sale: CFO Kevin Feeley sold 6,187 shares on Mar 4 at the same avg price (~$78.61) for ~ $486k, trimming his stake by ~24.9%. Smaller than the institutional buys but adds to mixed insider signals. SEC Form 4 — CFO sale
About GeneDx
(
Get Free Report)
GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.
Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
